Optimisation versus certainty: Understanding the issue of heterogeneity in economic evaluation

Social Science and Medicine

Volumn 58, Issue 2, 2004, Pages 315-320

  Stevens, Warren ^a   Normand, Charles ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Certainty; Cost effectiveness; Health gain; Heterogeneity; Optimisation

Indexed keywords

HEALTH CARE;

ANALYTICAL ERROR; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROMOTION; HEALTH STATISTICS; HUMAN; MEDICAL ASSESSMENT; ORGANIZATION; POPULATION; QUALITY ADJUSTED LIFE YEAR; UNCERTAINTY;

EID: 0242361174     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(03)00215-6     Document Type: Article

References (24)

1. Birch S. As a matter of fact. Evidence-based decision-making unplugged Health Economics. 6:1997;47-59.
2. Briggs A., Fenn P. Trying to do better than average. A commentary on statistical inference for cost-effectiveness ratios Health Economics. 6:1997;491-495.
3. Bulpitt C. Subgroup analysis. Lancet. 2(8601):1988;31-34.
4. Buyse M.E. Analysis of clinical trial outcomes. Some comments on subgroup analysis Controlled Clinical Trials. 10:1989;S187-119.
5. Claxton K. The irrelevance of inference. A decision making approach to the stochastic evaluation of health care technologies Journal of Health Economics. 18:1999;341-364.
6. Claxton K. Bayesian approaches to the value of information. Implications for the regulation of new pharmaceuticals Health Economics. 8:1999;269-274.
7. Claxton K., Thompson K.M. A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics. 20:2001;797-822.
8. Claxton K., Neumann P.J., Araki S., Weinstein M.C. Bayesian value of information analysis. An application to a model of Alzheimer's disease. International Journal of Technology Assessment in Health Care. 17:2001;38-55.
9. Counsell C.E., Clarke M.J., Slattery J., Sandercock P.A.G. The miracle of DICE therapy for acute stroke. Fact or fictional product of subgroup analysis British Medical Journal. 309:1994;1677-1681.
10. Dowie J. Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium. Health Economics. 7:1998;93-103.
11. Fry, T. C. (1933). A mathematical theory of rational inference. Notes from a lecture given to the Econometric Society. Chicago.
12. Larson E.B. Dealing with limited resources. The Oregon decision to curtail funding for organ transplantation. New England Journal of Medicine. 319:1988;171-173.
13. Loomes G., McKenzie L. The use of QALYs in health care decision-making. Social Science & Medicine. 28:1989;299-308.
14. Lopert R., Lang D.L., Hill S.R., Henry D.A. Differential pricing of drugs. A role in cost-effectiveness analysis? Lancet. 359:2002;2105-2107.
15. Luce B.R., Claxton K. Redefining the analytical approach to pharmacoeconomics. Health Economics. 8:1999;187-189.
16. Mauri F., Gasparini M., Barbonaglia L., Santoro E., Grazia Franzosi M., Tognoni G., Rovelli F. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). American Journal of Cardiology. 63(18):1989;1291-1295.
17. Michels K.B., Rosner B.A. Data trawling. To fish or not to fish Lancet. 348(9035):1996;1152-1153.
18. Neumann P.J., Claxton K., Weinstein M.C. The FDA's regulation of health economic information. Heath Affairs. 19:2000;129-137.
19. Oxman A.D., Guyatt G.H. A consumer's guide to subgroup analysis. Annals of Internal Medicine. 116:1992;78-84.
20. Peto R. Misleading subgroup analyses in GISSI. American Journal of Cardiology. 66(7):1990;771-772.
21. Sculpher M., Gafni A. Recognizing diversity in public preferences. The use of preference sub-groups in cost-effectiveness analysis Health Economics. 10(4):2001;317-324.
22. Sendi P., Gafni A., Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Economics. 11(1):2002;23-31.
23. Willan A.R., O'Brien B.J. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Economics. 8(3):1999;203-211.
24. Yusuf S., Collins R., Peto R. Why do we need some large, simple randomised controlled trials? Statistics in Medicine. 3:1984;409-420.